Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127871681 | 12787168 | 1 | I | 201605 | 20160922 | 20160927 | 20160927 | EXP | FR-009507513-1609FRA011654 | MERCK | 60.67 | YR | F | Y | 48.00000 | KG | 20160927 | OT | FR | FR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 127871681 | 12787168 | 1 | PS | CANCIDAS | CASPOFUNGIN ACETATE | 1 | Intravenous (not otherwise specified) | 70 MG, QD | N | 21227 | 70 | MG | INJECTION | QD | |||||
| 127871681 | 12787168 | 2 | SS | CANCIDAS | CASPOFUNGIN ACETATE | 1 | Intravenous (not otherwise specified) | 50 MG, QD | N | 21227 | 50 | MG | INJECTION | QD | |||||
| 127871681 | 12787168 | 3 | SS | IMIPENEM AND CILASTATIN | CILASTATIN SODIUMIMIPENEM | 1 | Intravenous (not otherwise specified) | UNK | N | 0 | INTRAVENOUS INJECTION | ||||||||
| 127871681 | 12787168 | 4 | SS | MEROPENEM. | MEROPENEM | 1 | Intravenous (not otherwise specified) | 2 G, TID | N | 0 | 2 | G | TID | ||||||
| 127871681 | 12787168 | 5 | SS | TARGOCID | TEICOPLANIN | 1 | Intravenous (not otherwise specified) | 400 MG, BID | N | 0 | 400 | MG | BID | ||||||
| 127871681 | 12787168 | 6 | SS | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 400 MG, QD | N | 0 | 400 | MG | QD | ||||||
| 127871681 | 12787168 | 7 | SS | BACTRIM | SULFAMETHOXAZOLETRIMETHOPRIM | 1 | Oral | 200 MG, QD | N | 0 | 200 | MG | QD | ||||||
| 127871681 | 12787168 | 8 | SS | PANTOPRAZOLE | PANTOPRAZOLE SODIUM | 1 | Intravenous (not otherwise specified) | UNK | N | 0 | |||||||||
| 127871681 | 12787168 | 9 | SS | ZYVOXID | LINEZOLID | 1 | Intravenous (not otherwise specified) | UNK | N | 0 | |||||||||
| 127871681 | 12787168 | 10 | SS | LANSOPRAZOLE. | LANSOPRAZOLE | 1 | Oral | 30 MG, QD | N | 0 | 30 | MG | QD |
Indications of drugs used
| no results found |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 127871681 | 12787168 | HO |
| 127871681 | 12787168 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 127871681 | 12787168 | Cholestasis | |
| 127871681 | 12787168 | Hepatocellular injury | |
| 127871681 | 12787168 | Hyperbilirubinaemia | |
| 127871681 | 12787168 | Vanishing bile duct syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 127871681 | 12787168 | 1 | 20160509 | 201605 | 0 | |
| 127871681 | 12787168 | 2 | 201605 | 20160513 | 0 | |
| 127871681 | 12787168 | 3 | 20160516 | 20160525 | 0 | |
| 127871681 | 12787168 | 4 | 20160502 | 20160513 | 0 | |
| 127871681 | 12787168 | 5 | 20160508 | 20160513 | 0 | |
| 127871681 | 12787168 | 6 | 20160515 | 20160520 | 0 | |
| 127871681 | 12787168 | 7 | 20160520 | 20160530 | 0 | |
| 127871681 | 12787168 | 8 | 20160429 | 201605 | 0 | |
| 127871681 | 12787168 | 9 | 20160516 | 20160524 | 0 | |
| 127871681 | 12787168 | 10 | 201605 | 20160829 | 0 |